Avanos Medical, a leader in medical technology, has announced that it has acquired Nexus Medical, a privately owned medical device company headquartered in Lenexa, Kansas. This move strengthens Avanos’ position in the critical care market, particularly in the delivery of nutrition and medication for patients in high-acuity settings.
Nexus Medical is best known for developing the TKO anti-reflux needleless connector, a specialized device designed to make intravenous nutrition and medication delivery safer and more consistent. This technology is critical in Neonatal and Pediatric Intensive Care Units, where patients are among the most vulnerable and require precise, reliable care.
The TKO connector uses a patented, pressure-activated tri-seal silicone valve that helps prevent blood from flowing back into the catheter. This is a significant advantage because blood reflux can lead to catheter blockages, delays in treatment, and an increased risk of infection. By mitigating these risks, the device enables uninterrupted therapy and improves patient outcomes.
For Avanos, the acquisition adds an important new tool to its Specialty Nutrition Systems business. It aligns with the company’s ongoing commitment to providing safe, dependable solutions for delivering therapy to neonatal and pediatric patients. The addition of Nexus’ technology will enable Avanos to offer a more comprehensive range of products to hospitals and healthcare providers, thereby helping them enhance patient safety and efficiency in critical care environments.
The acquisition was funded entirely with Avanos’ available cash, reflecting the company’s strong financial position. Avanos expects the acquisition to contribute immediately to both revenue growth and earnings per share, signaling that the deal is not only strategically valuable but also financially beneficial.
KEY QUOTES:
“This acquisition is a clear extension of our strategy to deliver smarter, safer solutions across the critical care spectrum. We are proud to add the Nexus TKO technology and the full breadth of Nexus’ offerings to our portfolio as we continue investing in meaningful innovation that helps clinicians provide consistent care and improve outcomes for patients who need it most.”
Dave Pacitti, Avanos chief executive officer
“Nexus TKO fits naturally into our Specialty Nutrition Systems business and is expected to deliver immediate value in NICU and PICU care. It’s a practical, trusted solution that helps clinicians reduce disruptions and deliver therapy with greater consistency and ease.”
Kerr Holbrook, Avanos’ chief commercial officer
